| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Se NCT05256225 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at th NCT04494113 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a NCT03914612 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial NCT05049538 | M.D. Anderson Cancer Center | — |
| Withdrawn | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer NCT03836157 | University of Oklahoma | Phase 2 |
| Active Not Recruiting | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and C NCT03660826 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer NCT03422198 | University of Utah | Phase 3 |
| Completed | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT02728258 | NRG Oncology | Phase 2 |
| Unknown | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer NCT02874430 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed NCT02501954 | Women's Cancer Care Associates, LLC | Phase 3 |
| Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Und NCT02315469 | NRG Oncology | — |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC- NCT02112552 | Albert Einstein College of Medicine | Phase 2 |
| Unknown | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or NCT02065687 | Gynecologic Oncology Group | Phase 2 / Phase 3 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Completed | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01935973 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT01935934 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer NCT01737619 | M.D. Anderson Cancer Center | N/A |
| Completed | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01642082 | Gynecologic Oncology Group | Phase 2 |
| Completed | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01225887 | Gynecologic Oncology Group | Phase 2 |
| Completed | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer NCT01440998 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT01210222 | Gynecologic Oncology Group | Phase 2 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer NCT01307631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01132820 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer NCT01344837 | Gynecologic Oncology Group | — |
| Completed | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Tr NCT01005329 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carbopla NCT00977574 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00888173 | Gynecologic Oncology Group | Phase 2 |
| Unknown | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, NCT00942357 | Gynecologic Oncology Group | Phase 3 |
| Unknown | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patient NCT00807768 | Gynecologic Oncology Group | Phase 3 |
| Completed | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV En NCT00575952 | Gynecologic Oncology Group | Phase 1 |
| Completed | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT00478426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III NCT00006011 | Gynecologic Oncology Group | Phase 3 |
| Completed | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Ca NCT00005840 | Gynecologic Oncology Group | Phase 1 |
| Completed | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Ca NCT00005830 | Gynecologic Oncology Group | Phase 1 |